Rivaroxaban - Revision history

Danbot: Added AF main page link to See Also

2026-03-25T01:18:11Z

Added AF main page link to See Also

← Revisión anterior		Revisión del 01:18 25 mar 2026
Línea 65:		Línea 65:
	*[[Back pain]]		*[[Back pain]]
	*[[Pruritus]]		*[[Pruritus]]
	*Elevated ALT		*Elevated ALT
	*[[Thrombocytopenia]]		*[[Thrombocytopenia]]

Línea 74:		Línea 74:

	==Mechanism of Action==		==Mechanism of Action==
	*Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways		*Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways


	==Indications by Condition==		==Indications by Condition==
	''The following table is automatically generated from disease/condition pages across WikEM.''		''The following table is automatically generated from disease/condition pages across WikEM.''

	{{#ask:[[Has DrugName::Rivaroxaban]]		{{#ask:[[Has DrugName::Rivaroxaban]]
	\|?Has Indication=Indication		\|?Has Indication=Indication
	\|?Has Dose=Dose		\|?Has Dose=Dose
	\|?Has Context=Context		\|?Has Context=Context
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=table		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50
	}}		}}

Línea 96:		Línea 94:
	*[[Anticoagulant reversal for life-threatening bleeds]]		*[[Anticoagulant reversal for life-threatening bleeds]]
	*[[Andexanet alfa]]		*[[Andexanet alfa]]
			*[[Atrial fibrillation (main)]]

	==References==		==References==
Línea 101:		Línea 100:
	*Epocrates		*Epocrates
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:58:01Z

Switch SMW query from broadtable to table format for better layout with TOC

← Revisión anterior		Revisión del 21:58 20 mar 2026
Línea 86:		Línea 86:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T17:25:54Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

← Revisión anterior		Revisión del 17:25 20 mar 2026
Línea 88:		Línea 88:
	\|format=broadtable		\|format=broadtable
	\|headers=plain		\|headers=plain
	\|~~link~~=~~subject~~		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50

Danbot: Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

2026-03-20T16:44:04Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

@@ Línea 75: / Línea 75: @@
 ==Mechanism of Action==
 *Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways
 ==See Also==

Ostermayer: /* DVT/PE Treatment */

2023-10-19T02:55:42Z

DVT/PE Treatment

← Revisión anterior		Revisión del 02:55 19 oct 2023
Línea 16:		Línea 16:

	===[[DVT]]/[[PE]] Treatment===		===[[DVT]]/[[PE]] Treatment===
	*15mg twice daily x 21 days if CrCl ≥15		*15mg twice daily x 21 days if CrCl ≥15<ref>Xarelto https://www.xareltohcp.com/dvt-pe/initial/dosing</ref>
	*20mg once daily starting day 22 if CrCl ≥15		*20mg once daily starting day 22 if CrCl ≥15

Ostermayer: /* Adult Dosing */

2023-10-19T02:55:01Z

Adult Dosing

← Revisión anterior		Revisión del 02:55 19 oct 2023
Línea 13:		Línea 13:

	===[[DVT]]/[[PE]] Prophylaxis, recurrent===		===[[DVT]]/[[PE]] Prophylaxis, recurrent===
	*20mg PO QD		*20mg PO once daily

	===[[DVT]]/[[PE]] Treatment===		===[[DVT]]/[[PE]] Treatment===
	*20mg ~~PO QD~~		*15mg twice daily x 21 days if CrCl ≥15
			*20mg once daily starting day 22 if CrCl ≥15

	===[[Atrial fibrillation]] and new stent<ref>Gibson CM et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 Nov 14.</ref>===		===[[Atrial fibrillation]] and new stent<ref>Gibson CM et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 Nov 14.</ref>===

Rossdonaldson1: /* Adult Dosing */

2023-06-07T22:23:45Z

Adult Dosing

← Revisión anterior		Revisión del 22:23 7 jun 2023
Línea 6:		Línea 6:

	==Adult Dosing==		==Adult Dosing==
	*Thromboembolism/[[stroke]] prophylaxis: 20mg PO QD		===Thromboembolism/[[stroke]] prophylaxis===
	*[[DVT]] Prophylaxis: 10mg PO QD x35 days; Start: 6-10h post-op once hemostasis established		*20mg PO QD
	*[[DVT]]/[[PE]] Prophylaxis, recurrent: 20mg PO QD
	*[[DVT]]/[[PE]] Treatment: 20mg PO QD		===[[DVT]] Prophylaxis===
	*[[Atrial fibrillation]] and new stent<ref>Gibson CM et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 Nov 14.</ref>:		*10mg PO QD x35 days; Start: 6-10h post-op once hemostasis established
	**Rivaroxaban 15 mg/day plus [[clopidogrel]] for 12 months post-stenting just as efficacious to current standard
	**Reduces clinically significant bleeds from ~27% to 17% as compared to [[warfarin]] plus DAPT		===[[DVT]]/[[PE]] Prophylaxis, recurrent===
			*20mg PO QD

			===[[DVT]]/[[PE]] Treatment===
			*20mg PO QD

			===[[Atrial fibrillation]] and new stent<ref>Gibson CM et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 Nov 14.</ref>===
			*Rivaroxaban 15 mg/day plus [[clopidogrel]] for 12 months post-stenting just as efficacious to current standard
			*Reduces clinically significant bleeds from ~27% to 17% as compared to [[warfarin]] plus DAPT

	==Special Populations==		==Special Populations==

Elcatracho: /* Administration */

2021-03-08T16:11:11Z

Administration

← Revisión anterior		Revisión del 16:11 8 mar 2021
Línea 1:		Línea 1:
	==Administration==		==Administration==
	*Type: [[Anticoagulant]], Factor Xa Inhibitor		*Type: [[Anticoagulant]], Factor Xa Inhibitor
	*Dosage Forms: 10, 15, 20		*Dosage Forms: 10mg, 15mg, 20mg
	*Routes of Administration:		*Routes of Administration:
	*Common Trade Names: Xarelto		*Common Trade Names: Xarelto

Elcatracho: /* Adult Dosing */

2021-02-25T13:58:14Z

Adult Dosing

← Revisión anterior		Revisión del 13:58 25 feb 2021
Línea 12:		Línea 12:
	*[[Atrial fibrillation]] and new stent<ref>Gibson CM et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 Nov 14.</ref>:		*[[Atrial fibrillation]] and new stent<ref>Gibson CM et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 Nov 14.</ref>:
	**Rivaroxaban 15 mg/day plus [[clopidogrel]] for 12 months post-stenting just as efficacious to current standard		**Rivaroxaban 15 mg/day plus [[clopidogrel]] for 12 months post-stenting just as efficacious to current standard
	**Reduces clinically significant bleeds from ~27% to 17% as compared to warfarin plus DAPT		**Reduces clinically significant bleeds from ~27% to 17% as compared to [[warfarin]] plus DAPT

	==Special Populations==		==Special Populations==

ClaireLewis: /* Administration */

2019-09-19T17:57:54Z

Administration

← Revisión anterior		Revisión del 17:57 19 sep 2019
Línea 1:		Línea 1:
	==Administration==		==Administration==
	*Type: Anticoagulant, Factor Xa Inhibitor		*Type: [[Anticoagulant]], Factor Xa Inhibitor
	*Dosage Forms: 10, 15, 20		*Dosage Forms: 10, 15, 20
	*Routes of Administration:		*Routes of Administration: